(2026). Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era. Rare Cancers and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era."
Rare Cancers and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era."
Rare Cancers and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.